AAIC: Roche ‘very interested’ in testing tau for Alzheimer’s despite focus on phase 3-stage amyloid drug

Roche’s biggest bet in the Alzheimer’s disease space may be its phase 3-stage amyloid asset, but the Swiss pharma is keeping its options open when it comes to targeting tau.